|
1
|
Ban KA and Godellas CV: Epidemiology of
breast cancer. Surg Oncol Clin N Am. 23:409–422. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee EY and Muller WJ: Oncogenes and tumor
suppressor genes. Cold Spring Harb Perspect Biol. 2:a0032362010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sieburth DS, Sun Q and Han M: SUR-8, a
conserved Ras-binding protein with leucine-rich repeats, positively
regulates Ras-mediated signaling in C. elegans. Cell. 94:119–130.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jang ER, Jang H, Shi P, Popa G, Jeoung M
and Galperin E: Spatial control of Shoc2-scaffold-mediated ERK1/2
signaling requires remodeling activity of the ATPase PSMC5. J Cell
Sci. 128:4428–4441. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Matsunaga-Udagawa R, Fujita Y, Yoshiki S,
Terai K, Kamioka Y, Kiyokawa E, Yugi K, Aoki K and Matsuda M: The
scaffold protein Shoc2/SUR-8 accelerates the interaction of Ras and
Raf. J Biol Chem. 285:7818–7826. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li W, Han M and Guan KL: The leucine-rich
repeat protein SUR-8 enhances MAP kinase activation and forms a
complex with Ras and Raf. Genes Dev. 14:895–900. 2000.PubMed/NCBI
|
|
8
|
Rodriguez-Viciana P, Oses-Prieto J,
Burlingame A, Fried M and McCormick F: A phosphatase holoenzyme
comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions
as an M-Ras effector to modulate Raf activity. Mol Cell.
22:217–230. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shaw AS and Filbert EL: Scaffold proteins
and immune-cell signalling. Nat Rev Immunol. 9:47–56. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rouchka EC, Jeoung M, Jang ER, Liu J, Wang
C, Li X and Galperin E: Data set for transcriptional response to
depletion of the Shoc2 scaffolding protein. Data Brief. 7:770–778.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Young LC, Hartig N, Munoz-Alegre M,
Oses-Prieto JA, Durdu S, Bender S, Vijayakumar V, Vietri Rudan M,
Gewinner C, Henderson S, et al: An MRAS, SHOC2, and SCRIB complex
coordinates ERK pathway activation with polarity and tumorigenic
growth. Mol Cell. 52:679–692. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee YM, Kaduwal S, Lee KH, Park JC, Jeong
WJ and Choi KY: Sur8 mediates tumorigenesis and metastasis in
colorectal cancer. Exp Mol Med. 48:e2492016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaduwal S, Jeong WJ, Park JC, Lee KH, Lee
YM, Jeon SH, Lim YB, Min do S and Choi KY: Sur8/Shoc2 promotes cell
motility and metastasis through activation of Ras-PI3K signaling.
Oncotarget. 6:33091–33105. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kaplan FM, Kugel CH III, Dadpey N, Shao Y,
Abel EV and Aplin AE: SHOC2 and CRAF mediate ERK1/2 reactivation in
mutant NRAS-mediated resistance to RAF inhibitor. J Biol Chem.
287:41797–41807. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Traini S, Piccolo E, Tinari N, Rossi C, La
Sorda R, Spinella F, Bagnato A, Lattanzio R, D'Egidio M, Di Risio
A, et al: Inhibition of tumor growth and angiogenesis by SP-2, an
anti-lectin, galactoside-binding soluble 3 binding protein
(LGALS3BP) antibody. Mol Cancer Ther. 13:916–925. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jeoung M, Jang ER, Liu J, Wang C, Rouchka
EC, Li X and Galperin E: Shoc2-tranduced ERK1/2 motility
signals--Novel insights from functional genomics. Cell Signal.
28:448–459. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aran D, Camarda R, Odegaard J, Paik H,
Oskotsky B, Krings G, Goga A, Sirota M and Butte AJ: Comprehensive
analysis of normal adjacent to tumor transcriptomes. Nat Commun.
8:10772017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li C, Cao L, Xu C, Liu F, Xiang G, Liu X,
Jiao J and Niu Y: The immunohistochemical expression and potential
prognostic value of HDAC6 and AR in invasive breast cancer. Hum
Pathol. 75:16–25. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ye W, Chen C, Gao Y, Zheng ZS, Xu Y, Yun
M, Weng HW, Xie D, Ye S and Zhang JX: Overexpression of SLC34A2 is
an independent prognostic indicator in bladder cancer and its
depletion suppresses tumor growth via decreasing c-Myc expression
and transcriptional activity. Cell Death Dis. 8:e25812017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shen Q, Yao Q, Sun J, Feng L, Lu H, Ma Y,
Liu L, Wang F, Li J, Yue Y, et al: Downregulation of histone
deacetylase 1 by microRNA-520h contributes to the chemotherapeutic
effect of doxorubicin. FEBS Lett. 588:184–191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin X, Yu Y, Zhao H, Zhang Y, Manela J and
Tonetti DA: Overexpression of PKCalpha is required to impart
estradiol inhibition and tamoxifen-resistance in a T47D human
breast cancer tumor model. Carcinogenesis. 27:1538–1546. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Clark GJ and Der CJ: Aberrant function of
the Ras signal transduction pathway in human breast cancer. Breast
Cancer Res Treat. 35:133–144. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eckert LB, Repasky GA, Ulku AS, McFall A,
Zhou H, Sartor CI and Der CJ: Involvement of Ras activation in
human breast cancer cell signaling, invasion, and anoikis. Cancer
Res. 64:4585–4592. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jones GG, Del Rio IB, Sari S, Sekerim A,
Young LC, Hartig N, Areso Zubiaur I, El-Bahrawy MA, Hynds RE, Lei
W, et al: SHOC2 phosphatase-dependent RAF dimerization mediates
resistance to MEK inhibition in RAS-mutant cancers. Nat Commun.
10:25322019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jang ER and Galperin E: The function of
Shoc2: A scaffold and beyond. Commun Integr Biol. 9:e11882412016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Loboda A, Nebozhyn M, Klinghoffer R,
Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M,
Haines B, et al: A gene expression signature of RAS pathway
dependence predicts response to PI3K and RAS pathway inhibitors and
expands the population of RAS pathway activated tumors. BMC Med
Genomics. 3:262010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li W, Liang RR, Zhou C, Wu MY, Lian L,
Yuan GF, Wang MY, Xie X, Shou LM, Gong FR, et al: The association
between expressions of Ras and CD68 in the angiogenesis of breast
cancers. Cancer Cell Int. 15:172015. View Article : Google Scholar : PubMed/NCBI
|
